Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Drug Review Review Pathway

New EU Filings

  • News

Executive Summary

Vutrisiran, Alnylam’s investigational RNAi therapeutic for treating hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy, is among the latest new medicines that have been submitted for review for potential pan-EU approval.

You may also be interested in...



Gilead’s Long-Acting HIV Drug Among Latest EU Filings

The European Medicines Agency has added seven new products to its list of medicines that are under review for potential EU marketing authorization.

Mobocertinib, Asciminib & Surufatinib Among Latest New Filings In EU

The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.

EU Crunch Time For Mirikizumab, New Covid-19 Vaccine & Other Drugs

The European Medicines Agency’s human medicines committee, the CHMP, is this week deciding whether to back marketing approval for eight new drugs and a coronavirus vaccine.

Table

View full table

Topics

Related Companies

Tags:
Europe Drug Review Review Pathway
Latest Headlines

Supreme Court Seems Ready To Uphold Ruling Against Amgen’s Anti-PCSK9 Antibody Patents

Vaccine Decisions: US FDA And CDC Weigh New Vaccines For Diseases From Dengue To RSV

Neonatal Drug Development Could Benefit From Rare Disease Experience

At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion

See All
UsernamePublicRestriction

Register

PS144964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By